{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:43:01Z","timestamp":1786236181514,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007120","name":"King Mongkut's Institute of Technology Ladkrabang","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004944","name":"Naresuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejphar.2026.179154","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:45:29Z","timestamp":1784270729000},"page":"179154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Selective pulmonary vasorelaxant effects of an N2,N4-diaminoquinazoline PDE5 inhibitor involving endothelial signaling and ion channel modulation"],"prefix":"10.1016","volume":"1030","author":[{"given":"Usana","family":"Chatturong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tipparat","family":"Meebangsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5072-1397","authenticated-orcid":false,"given":"Guntur","family":"Guntur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6998-7446","authenticated-orcid":false,"given":"M. Paul","family":"Gleeson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6973-158X","authenticated-orcid":false,"given":"Krongkarn","family":"Chootip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179154_bib1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1183\/13993003.00798-2015","article-title":"Potassium channels in pulmonary arterial hypertension","volume":"46","author":"Boucherat","year":"2015","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejphar.2026.179154_bib2","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.bmcl.2005.02.083","article-title":"Optimization of purine based PDE1\/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED","volume":"15","author":"Boyle","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2026.179154_bib3","doi-asserted-by":"crossref","first-page":"W324","DOI":"10.1093\/nar\/gkae300","article-title":"SwissDock 2024: major enhancements for small-molecule docking with Attracting Cavities and AutoDock Vina","volume":"52","author":"Bugnon","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2026.179154_bib4","first-page":"257","article-title":"The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases","volume":"2014","author":"Butrous","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"key":"10.1016\/j.ejphar.2026.179154_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2020.111311","article-title":"Type 5 phosphodiesterase (PDE5) and the vascular tree: from embryogenesis to aging and disease","volume":"190","author":"Cesarini","year":"2020","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.ejphar.2026.179154_bib6","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/pharmaceutics17081047","article-title":"Enhancing chemical stability and bioavailability of aneratrigine capsules via dry granulation: addressing stability challenges in sodium bicarbonate-containing formulations for clinical development","volume":"17","author":"Cha","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2026.179154_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3390\/toxins9040122","article-title":"A pharmacological examination of the cardiovascular effects of Malayan Krait (Bungarus candidus) venoms","volume":"9","author":"Chaisakul","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.ejphar.2026.179154_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.107111","article-title":"Quinazoline-based human phosphodiesterase 5 inhibitors exhibited a selective vasorelaxant effect on rat isolated pulmonary arteries involving NO-sGC-cGMP pathway and calcium inhibitory effects","volume":"147","author":"Chatturong","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179154_bib9","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.3390\/ijms26094265","article-title":"Vascular remodeling: the multicellular mechanisms of pulmonary hypertension","volume":"26","author":"Dai","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2026.179154_bib10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2174\/138945012802002348","article-title":"Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview","volume":"13","author":"Evora","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2026.179154_bib11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1021\/ci900022h","article-title":"QM\/MM as a tool in fragment based drug discovery. A cross-docking, rescoring study of kinase inhibitors","volume":"49","author":"Gleeson","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejphar.2026.179154_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111629","article-title":"Revisiting the large-conductance calcium-activated potassium (BKCa) channels in the pulmonary circulation","volume":"11","author":"Guntur","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2026.179154_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1527-3458.2000.tb00141.x","article-title":"Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor","volume":"6","author":"Hainsworth","year":"2000","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.ejphar.2026.179154_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1161\/01.RES.0000196742.65848.56","article-title":"Potassium channels and proliferation of vascular smooth muscle cells","volume":"97","author":"Jackson","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2026.179154_bib15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jep.2011.06.045","article-title":"Bacopa monnieri and its constituents is hypotensive in anaesthetized rats and vasodilator in various artery types","volume":"137","author":"Kamkaew","year":"2011","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ejphar.2026.179154_bib16","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.amjcard.2017.06.012","article-title":"The nitric oxide pathway in pulmonary vascular disease","volume":"120","author":"Klinger","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2026.179154_bib17","doi-asserted-by":"crossref","first-page":"5851","DOI":"10.1021\/jm060999m","article-title":"Prediction of protein-ligand interactions. Docking and scoring: successes and gaps","volume":"49","author":"Leach","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.179154_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.70050","article-title":"The role of ion channels in pulmonary hypertension: a review","volume":"15","author":"Li","year":"2025","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ejphar.2026.179154_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/resp.13392","article-title":"Pulmonary arterial hypertension in a multi-ethnic Asian population: characteristics, survival and mortality predictors from a 14-year follow-up study","volume":"24","author":"Lim","year":"2019","journal-title":"Respirology"},{"key":"10.1016\/j.ejphar.2026.179154_bib20","first-page":"Cd014089","article-title":"Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon","volume":"11","author":"Maltez","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2026.179154_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/HYPERTENSIONAHA.119.12992","article-title":"Pulmonary hypertension and ATP-sensitive potassium channels","volume":"74","author":"McClenaghan","year":"2019","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2026.179154_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.sxmr.2021.10.004","article-title":"Recreational use of oral PDE5 inhibitors: the other side of midnight","volume":"10","author":"Mostafa","year":"2022","journal-title":"Sexual Medicine Reviews"},{"key":"10.1016\/j.ejphar.2026.179154_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24020281","article-title":"Elucidation of vasodilation response and structure activity relationships of N2,N4-Disubstituted quinazoline 2,4-Diamines in a rat pulmonary artery model","author":"Paracha","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2026.179154_bib24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bmcl.2018.11.043","article-title":"Design, synthesis and evaluation of N2,N4-diaminoquinazoline based inhibitors of phosphodiesterase type 5","volume":"29","author":"Pobsuk","year":"2019","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2026.179154_bib25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/biom12101341","article-title":"Potassium channels as therapeutic targets in pulmonary arterial hypertension","volume":"12","author":"Redel-Traub","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejphar.2026.179154_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17534666251367312","article-title":"Advances in diagnosis and patient profiling in pulmonary arterial hypertension for precision medicine","volume":"19","author":"Ricchi","year":"2025","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.ejphar.2026.179154_bib27","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.179154_bib28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3390\/life15030430","article-title":"Management of pulmonary arterial hypertension: current strategies and future prospects","volume":"15","author":"Sharma","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.ejphar.2026.179154_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117092","article-title":"Computational design, synthesis and biological evaluation of PDE5 inhibitors based on N2,N4-diaminoquinazoline and N2,N6-diaminopurine scaffolds","volume":"76","author":"Somnarin","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.179154_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120270","article-title":"Effects of phosphodiesterase 5 inhibition on cardiovascular function in resistant hypertension: a systematic review","volume":"291","author":"Storch","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2026.179154_bib31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s41232-024-00363-0","article-title":"Ca2+ signaling in vascular smooth muscle and endothelial cells in blood vessel remodeling: a review","volume":"44","author":"Suzuki","year":"2024","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.ejphar.2026.179154_bib32","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1021\/jm00039a024","article-title":"Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-Substitution of quinazoline derivatives for potent and selective inhibitory activity","volume":"37","author":"Takase","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.179154_bib33","doi-asserted-by":"crossref","DOI":"10.3791\/63686","article-title":"Isolation of intrapulmonary artery and smooth muscle cells to investigate vascular responses","author":"To-On","year":"2022","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejphar.2026.179154_bib34","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s10741-022-10239-5","article-title":"Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure","volume":"27","author":"Triposkiadis","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2026.179154_bib35","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/jm050362n","article-title":"A critical assessment of docking programs and scoring functions","volume":"49","author":"Warren","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2026.179154_bib36","first-page":"14","article-title":"Decoding signaling mechanisms: unraveling the targets of guanylate cyclase agonists in cardiovascular and digestive diseases","volume":"ume","author":"Yin","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179154_bib37","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41586-019-1801-3","article-title":"Cryo-EM structures of Apo and antagonist-bound human Cav3.1","volume":"576","author":"Zhao","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179154_bib38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/jcc.24249","article-title":"Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape","volume":"37","author":"Zoete","year":"2016","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926006369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926006369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T00:26:29Z","timestamp":1786235189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926006369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":38,"alternative-id":["S0014299926006369"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179154","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective pulmonary vasorelaxant effects of an N2,N4-diaminoquinazoline PDE5 inhibitor involving endothelial signaling and ion channel modulation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179154","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179154"}}